Diverse RNAs in adipose-derived extracellular vesicles and their therapeutic potential

Pengyu Hong,1,2,3,4 Mei Yu,1,2,3 and Weidong Tian1,2,3,4

Adipose tissue, which is considered an energy storage and active endocrine organ, produces and secretes a large amount of adipokines to regulate distant targets through blood circulation, especially extracellular vesicles (EVs). As cell-derived, membranous nanoparticles, EVs have recently garnered great attention as novel mediators in establishing intercellular communications as well as in accelerating interorgan crosstalk. Studies have revealed that the RNAs, including coding RNAs (messenger RNAs) and noncoding RNAs (long noncoding RNAs, micro-RNAs, and circular RNAs) are key bioactive cargoes of EV functions in various pathophysiological processes, such as cell differentiation, metabolic homeostasis, immune signal transduction, and cancer. Moreover, certain EV-contained RNAs have gradually been recognized as novel biomarkers, prognostic indicators, or even therapeutic nanodrugs of diseases. Therefore, in this review, we comprehensively summarize different classes of RNAs presented in adipose-derived EVs and discuss their therapeutic potential according to the latest research progress to provide valuable knowledge in this area.

INTRODUCTION

Adipose tissue is generally composed of many heterogeneous cell types, such as adipose-derived stem cells (ASCs), preadipocytes, mature adipocytes, as well as fibroblasts, nerve cells, macrophages, endothelial cells, and muscle cells.1 Studies have demonstrated that adipose tissue should be regarded not only as an energy-storage organ but also as an endocrine organ that synthesizes and releases factors, especially “adipokines,” which function as secretory factors to communicate with other metabolic organs and regulate whole-body energy homeostasis.2,3 Certain soluble adipokines, such as leptin and adiponectin secreted by adipose-derived cells have been well studied.4 In addition to those traditional, soluble mediators, recent studies have shown that the RNAs transported by extracellular vesicles (EVs) can also exert adipokine-like functions.5 For example, micro RNAs (miRNAs) of EVs derived from adipose tissue can act as endocrine messengers that facilitate communication that ranges from nearby cells to distant tissues, and they are, therefore, considered a novel kind of adipokine.2,6,7 Importantly, the exploration and recognition of RNAs in EVs has progressed immensely because of the comprehensive use of high-throughput RNA sequencing and validation of quantitative polymerase chain reaction (qPCR), even though they are present in small amounts.7 Hence, studies have gradually acknowledged and appreciated more-functional RNAs mediated by EVs, which represent a novel mode of intercellular communication and may act as novel factors to exert potential therapeutic benefits.8 However, the RNA pools carried by EVs come from adipose-derived tissues and cells that have not yet been completely characterized. Therefore, in this review, we will illustrate the diverse RNAs in adipose-derived EVs and highlight their therapeutic potential according to the most-recent relevant literature to summarize practical and valuable knowledge in this area.

CHARACTERISTIC AND BIOGENESIS OF EXTRACELLULAR VESICLES

EVs are defined as nanoparticles released from cells and are delimited by a lipid bilayer, which does not have a functional nucleus and cannot replicate.7 EVs can be secreted by almost all cells and have been extracted from several body tissues, as well as varieties of body fluids, including urine, saliva, plasma, semen, breast milk, and lymph fluids.9,10 According to the size and biogenesis of EVs, there are three major types that produce them: exosomes, microvesicles (MVs), and apoptotic bodies.7 Here, in this review, we mainly discuss the first two types of EVs. Exosomes are produced from the endosomal pathway and are secreted as particles ranging from 40 nm to 160 nm in diameter.12 By contrast, MVs are vesicles produced by direct outward

1State Key Laboratory of Oral Disease & National Clinical Research Center for Oral Diseases West China School of Stomatology, Sichuan University, Chengdu, China; 2National Engineering Laboratory for Oral Regenerative Medicine, West China School of Stomatology, Sichuan University, Chengdu, China; 3Engineering Research Center of Oral Translational Medicine, Ministry of Education, Sichuan University, Chengdu, China; 4Department of Oral and Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu, China

E-mail: yumei925@hotmail.com
Correspondence: Prof. Weidong Tian, State Key Laboratory of Oral Disease & National Clinical Research Center for Oral Diseases West China School of Stomatology, Sichuan University, Chengdu, China. E-mail: drtwd@sina.com

https://doi.org/10.1016/j.omtn.2021.08.028.

Correspondence: Dr. Mei Yu, State Key Laboratory of Oral Disease & National Clinical Research Center for Oral Diseases West China School of Stomatology, Sichuan University, Chengdu, China. E-mail: yumei925@hotmail.com

This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
budding of the cell membrane and are on the order of 50–1,000 nm in diameter.\textsuperscript{13}

Exosomes and MVs have different modes of biogenesis. Exosomes are generally formed by invagination of the endosomal membrane forming intraluminal vesicles (ILVs) within multivesicular bodies (MVBs). First, early endosomes, formed by lipid raft domains of the plasma membrane, mature into late endosomes with the assistance of the Golgi complex. Then, the bilayer membrane of late endosomes produces ILVs, which accumulate in their lumen. Lastly, the ILVs fuse with the cell membrane and are released into the extracellular environment and are known as exosomes.\textsuperscript{15,14}

Regarding the formation of MVs, they are related to the molecular redistribution of the cell membrane bilayer, which includes phospholipids and proteins as well as Ca\textsuperscript{2+} levels.\textsuperscript{15} These processes generally include two major pathways: those dependent on the endosomal sorting complex required for transport (ESCRT), or those that are independent of the ESCRT.\textsuperscript{15} The ESCRT machinery is said to act in a stepwise manner, requiring a sequential performance of the four ESCRT subunits (ESCRT-0, -I, -II, and -III), associated proteins (ALG2-interacting protein X [ALIX] and vacuolar protein sorting-associated protein 4 [VPS4]), and lipid rafts.\textsuperscript{16} ESCRT0 and ESCRTI complexes cluster transmembrane cargo into the vesicles and recruit them via ESCRTII; then, the ESCRTIII subunits drive budding and fusing of the membranes, which finally produces exosomes.\textsuperscript{15} In addition, the ESCRT is also involved in MV formation and the last phase of their release. Studies indicate that arrestin domain-containing protein 1 (ARRDC1), an adaptor protein, recruits ESCRT proteins of the tumor susceptibility gene 101 (TSG101) and VPS4 to the cell membrane, which prompt them to bud out from the cell membrane and share many of the same functional cargoes as that of exosomes.\textsuperscript{17}

Research has shown that EVs extensively participate in physiological and pathological conditions.\textsuperscript{18–20} The main components of EVs contain a wide range of cargos (for example: proteins, RNAs, and lipids), which can be transferred between cells as a means of cell-cell communication at both paracrine levels and systemic levels.\textsuperscript{21,22} Of note, some RNA cargoes are found to be selectively incorporated into EVs.\textsuperscript{15} The transcriptomes of different cell types, even different cell differential states, are all partially reflected in their extracellular vesicle RNA cargo.\textsuperscript{23,2} For example, a recent study indicated that miRNAs contributing to brown fat cell differentiation are enriched in EVs derived from ASCs during beige adipogenic differentiation compared with EVs derived from ASCs during proliferation.\textsuperscript{24} When EVs are internalized, the complex, bioactive cargoes from their progenitor cells elicit diverse and pleiotropic responses in recipient cells, including angiogenesis, adipogenesis, osteogenesis, immune modulation, and cancer progression.\textsuperscript{25–28} Because of the multiple functions of EVs, these nanovesicles, whether they are derived from tissue or cells, are collectively reported to have therapeutic effects on tissue repair, wound healing, immune modulation, diabetes, oncology, therapy, and other diseases.\textsuperscript{29–33} Therefore, EVs have already displayed their critical and crucial role in cell-free therapeutic strategies, with huge potential, and have also aroused great concern in biomedical frontiers.

**DIVERSE RNAs IN ADIPOSE-DERIVED EXTRACELLULAR VESICLES**

In recent years, the exploration of diverse RNAs in adipose-derived EVs has progressed extensively because they are being investigated as novel biomarkers, pathophysiological mediators, and potential therapeutic drugs.\textsuperscript{2,34,35} These RNA populations include messenger RNAs (mRNAs), miRNAs, long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), transfer RNAs (tRNAs), small nucleolar RNAs (snRNAs), and PIWI-interacting RNAs (piRNAs).\textsuperscript{12,35–38} Relevant to the packaging of RNA cargoes into EVs, emerging studies have demonstrated that certain RNAs in EVs are selectively enriched compared with their parental cells.\textsuperscript{39} There is evidence that this kind of RNA sorting is a rigid and regulated process.\textsuperscript{40} For instance, specific RNA sequences are retained and then packaged by EVs, which are generally transferred by RNA-binding proteins (RBPs), including the heterogenous nuclear ribonucleoprotein (hnRNP) family, Argonaute 2 (Ago2), Y-box-binding protein 1 (YB-1), NOP2/Sun domain family member 2 protein (NSUN2), and others.\textsuperscript{41,42} Furthermore, multiple routes of EV uptake have been reported. RNAs containing EVs can enter recipient cells via clathrin/caveolin-mediated endocytosis, macropinocytosis, phagocytosis, lipid raft-mediated uptake, or direct membrane fusion (Figure 1).\textsuperscript{41,19,43} Although certain RNA functions in adipose-derived EVs are not yet known, the fact that these RNAs are able to be diverted from donor cells to recipient cells has suggested an important and indispensable communication system between cells. Therefore, in the following section, this review will discuss miRNAs, miRNAs, lncRNAs, and circRNAs contained in adipose-derived EVs.

**mRNA**

Early pioneer work has established that mRNAs are first synthesized in the cell nucleus, where they undergo splicing and modification, and then, they are transported to the cytoplasm, where they serve as protein translational templates before being degraded. Interestingly, Valadi et al.\textsuperscript{14} first found that there were mRNAs and miRNAs contained in exosomes, which could be delivered to other cells, and had different functional roles in those new locations. Recent studies have shown that full-length or fragmented mRNAs in various EVs can be carried as genetic cargoes and participate in a variety of physiological and pathological processes.\textsuperscript{45} For example, previous RNA sequencing and bioinformatic analyses have revealed that EVs that come from adipose-derived stem cells (EV-ASCs) preferentially express mRNA encoding for transcription factors that are involved in angiogenesis and adipogenesis (e.g., hairy and enhancer of split-1 [HES1], CREB–enhancer binding protein [CEBP]–alpha [CEBPα], transcription factor-4 [TF4], and Kruppel-like factor-7 [KLF7]), Golgi apparatus proteins, and proteins involved in transforming growth factor β (TGF-β) signaling.\textsuperscript{36,46} RNA sequencing also found that 255 mRNAs, more than 70% of which were related to transcription factors, were selectively upregulated in EV-ASCs versus ASCs.\textsuperscript{47} These data provide insights into the principal capabilities of EV-ASCs...
with respect to their potential to modulate molecular networks and interactions in the recipient cells.

Moreover, Müller et al.48 found that adipocyte-derived EVs contained specific transcripts and miRNAs, which could both be transferred into recipient adipocytes and were involved in the upregulation of lipogenesis and cell size. In addition, adipocyte-derived EVs were also able to transfer adipogenic miRNAs (peroxisome proliferator-activated receptors-gamma [PPARγ], leptin, CEBPz, and CEBPδ) and anti-osteoblastic miRNAs to osteoblasts, which results in the decreased expression of osteocalcin and osteopontin.49 Furthermore, miRNAs can also be engineered and modified in target adipose-derived EVs as novel genetic drugs and vehicles. For example, Chen et al.50 transfected a glial cell line-derived neurotrophic factor (GDNF; a neurotrophic factor that protects nigral dopaminergic neurons) into ASCs and successfully isolated GDNF-ASC-EVs, and then, identified the ability of those EVs to exert cytoprotective effects on human umbilical vein endothelial cells (HUVECs) by reducing hypoxia/ischemia injury. The migration, angiogenesis, and apoptosis-resistance capacities of HUVECs were all increased. Moreover, GDNF-ASC-EVs promoted SIRT1 signaling mediates antioxidant action, which is accompanied by increased levels of phosphorylated endothelial nitric oxide synthase.51 Collectively, miRNAs encapsulated in adipose-derived EVs not only can be directly transferred but also can be artificially modified before transfer; both of which may contribute to biological, functional changes in recipient cells.

miRNAs

miRNAs are a class of small noncoding RNAs (~22 nt), highly conserved, and single-stranded RNAs that can modulate the translational efficiency of their target mRNAs in various cell types.52 Studies have shown that miRNAs generally contain 6–8 nt seed sequences that can integrate with the 3′ untranslated regions (UTRs) of mRNAs.53 Binding of these miRNAs to target mRNAs recruits those mRNAs to the RNA-induced silencing complex (RISC) and, then, triggers mRNA silencing and degradation.54 Moreover, miRNAs are not only formed and exert their functions inside of cells but also can be released into the circulation and body fluids to participate in various intercellular signaling.55 Of note, miRNAs are found to be packaged within EVs and released by many types of cells and tissues, especially from adipose sources; of which, miRNAs serve as a new class of endocrine factors and adipokines.

One study conducted miRNA microarray analysis by comparing ASC-derived MVs and ASCs. Some miRNAs were found to be produced and selectively packaged into EVs; of which, nine miRNAs were downregulated in ASC-derived EVs, whereas 23 miRNAs were upregulated compared with ASCs.56 For example, two miRNA members of the let-7 family (let-7i-5p and let-7i-5p), which have been proven to promote angiogenesis, were more highly expressed in ASCs than they were in ASC-derived MVs.55,56 In addition, different miRNA profiles have been reported to be of different origins in adipose-derived EVs, implicating their distinct and indispensable roles in regulating biological processes. Zhang et al.57 profiled the miRNAs in exosome-like vesicles derived from adipose tissue (Exo-AT) and exosome-like vesicles derived from ASCs via using high-throughput sequencing. The results revealed 45 miRNAs were highly expressed in Exo-AT compared with the exosome-like vesicles derived from ASCs; of which, 14 miRNAs (e.g., miR-30a-5p and miR-148a-3p) were associated with adipogenesis, eight miRNAs (e.g., miR-93-5p and miR-150-3p) were demonstrated to repress osteoblastic differentiation of mesenchymal stem cells (MSCs), nine miRNAs (e.g., miR-150-3p and miR-126a-3p) were related to angiogenesis, and four miRNAs (such as miR-224) were associated with metabolic regulation.58 In addition, recent studies have demonstrated that adipose tissue macrophages (ATMs) are at the root of the aberrant inflammation in hypertrophic, chronic adipose-tissue inflammation, and they may exert critical functions in type 2 diabetes and insulin resistance.59,60 Moreover, evidence has revealed that exosomes derived from ATMs (Exo-ATMs) transferred miRNAs to insulin target cells, and deep sequencing of miRNAs from lean and obese Exo-ATMs have identified more than 500 miRNAs; among which, a set of miRNAs (such as miR-155), which was related to insulin sensitivity and glucose tolerance, was differentially expressed in obese versus lean Exo-ATMs.61

Because miRNAs have displayed great potential for therapeutic applications in altering gene expression locally and distantly, studies to date have employed a variety of methods to engineer and modify certain amounts of miRNAs transferred by EVs to achieve their aims. For example, Qu et al.59 demonstrated that exosomes derived from miR-181-5p-modified ASCs could reduce liver fibrosis through activating autophagy. Exosomes derived from miR-199a- and miR-122-modified ASCs could effectively improve hepatocellular carcinoma (HCC) chemosensitivity by directly enhancing the sensitivity of HCC cells.62,63 In addition, exosomes from miR-146a-overexpressing ASCs have been proven to exert therapeutic effects in relieving acute myocardial infarction (AMI)-induced myocardial damage.64 Collectively, because engineered miRNAs are currently just in their beginning stages, use of adipose-derived EVs as natural miRNA delivery vehicles has aroused great interest and concern. With the extensive studies conducted in miRNAs of adipose-derived EVs, this novel domain is anticipated to become prosperous, along with growing knowledge of the production, enrichment, transfer, and specific functions of miRNAs delivered by adipose-derived EVs.

lncRNAs

lncRNAs are currently defined as RNAs greater than 200 base pairs (bp) without protein-coding capacity.65 This is a broad definition that comprises a heterogeneous class of RNA transcripts, including promoters, enhancers, snoRNAs, intergenic transcripts, and transcripts that overlap other transcripts in either sense or antisense orientation.66 lncRNAs are demonstrated to engage in a variety of biological processes, such as cell differentiation, tumorigenesis, angiogenesis, immune reactions, and epigenetic regulation.67–69 Moreover, delivery of certain lncRNAs by EVs can exert curative effects on many diseases, among all organ systems.18 Certain star lncRNAs from EVs (such as MALAT1 and H19) have been proven to be related to cell
proliferation, apoptosis, adipogenesis, and tumorigenesis.\textsuperscript{70–72} Along with numerous types of lncRNAs found in EVs, there particular interest has been shown on the therapeutic potential for harnessing the internal mechanisms of this novel, intercellular type of RNA transfer.\textsuperscript{18} Currently, most lncRNA-related studies of adipose-derived EVs have concentrated on the interaction between miRNAs and mRNAs. Patel et al.,\textsuperscript{73} using RNA sequencing, demonstrated that the lncRNA MALAT1 in exosomes derived from ASCs (Exo-ASCs) affected not only mRNA expression but also the expression of noncoding RNAs, especially snoRNAs in a model of traumatic brain injury. On the other hand, the lncRNA MALAT1 in Exo-ASCs was demonstrated to promote fibroblast migration and angiogenesis in a wound-healing model.\textsuperscript{74} In addition, the adipocyte-derived exosomal lncRNA SNHG9 can directly bind to the tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) mRNAs, which, thus, constituted an RNA dimeric inducible-silencing complex and reduced endothelial dysfunction of obese patients.\textsuperscript{75} Further analysis has suggested that lncRNAs transferred by EVs could serve as sponges for miRNAs, thus, changing the expression of mRNAs indirectly. Shao et al.\textsuperscript{76} first uncovered and compared the profiles of exosomes derived from ASCs under hypoxia (Hyp/Exo-ASCs) and Exo-ASCs via high-throughput sequencing. The results revealed that expression of IncGm37494 was much greater in Hyp/Exo-ASCs than it was in Exo-ASCs, and its overexpression enhanced the M1/M2 polarization of microglial by suppressing miR-130b-3p and, thus, increasing the expression of PPARγ.\textsuperscript{76}

Although much has been learned concerning the critical roles of lncRNAs in different types of cells and tissues, as illustrated, studies concentrating on adipose-derived EVs are still, so far, limited. Further research is urgently needed to expand our understanding of these lncRNAs.

circRNA
circRNAs are classified as a novel group of tissue-specific endogenous noncoding RNAs expressed by the eukaryotic transcriptome.\textsuperscript{77} They are characterized by covalently bonded chains, continuous circle structures without a 5′ cap or a 3′ poly-A tail and that are much more resistant to digestion by RNase R exonuclease than linear RNAs are.\textsuperscript{78–80} To date, research using high-throughput RNA sequencing and microarray analyses have recognized various circRNAs that are selectively packaged into EVs.\textsuperscript{81–83} Furthermore, because circRNAs were demonstrated to be both contained in, and enriched in, EVs, researchers have started to explore the extracellular functions of those circRNAs, which have been found to exert critical roles in tumor immunity, cardiovascular diseases, and diabetes.\textsuperscript{84,85}

Similar to lncRNAs, most existing literature shows that circRNAs in adipose-derived EVs can interact with certain miRNAs and regulate...
the stability and translation of mRNA.\textsuperscript{86} Zhang et al.\textsuperscript{38} found that exosomes secreted from adipocytes can mediate the delivery of circ-deubiquitination (circ-DB), then suppress miR-34a, and activate the USP7/cyclin A2 signaling pathway. Shi et al.\textsuperscript{87} verified that overexpression of mmu_circ_0000250 increased the therapeutic effect of Exo-ASCs in accelerating wound healing in a model of diabetes by inhibiting expression of miR-128-3p and upregulating expression of SIRT1. Another study used bioinformatics analysis and a dual-luciferase reporter assay to predict and validate circHivep2 as being able to absorb miR-181a-5p to promote SOCS2 expression, and they subsequently used Exo-ASCs as a vehicle to deliver circHivep2 into animal models of epilepsy to enhance the therapeutic effects.\textsuperscript{83} In addition to this sponge-like function, circRNAs can combine with certain proteins to form circRNA-protein complexes (circRNPs) and perform regulatory effects.\textsuperscript{88} For example, circ_0075932, contained in adipocyte-derived exosomes, can directly bind with the RNA-binding protein Pumilio2 (PUM2), and upregulate Aurora A kinase, thereby motivating the nuclear factor κB (NF-κB) pathway.\textsuperscript{89} In general, circRNAs are more stable than linear RNAs are because they do not contain free ends and may not be disintegrated by exonucleases.\textsuperscript{7} Importantly, the widespread use of adipocyte-derived EVs has allowed more possibilities for the exploration of the circRNA functions on different cellular processes and cell fates.

**THERAPEUTIC POTENTIAL OF RNAs IN ADIPOSE-DERIVED EVs**

The therapeutic potential of RNAs in adipose-derived EVs has been proven in a variety of diseases, which is essential for progress in future clinical applications, such as metabolic dysfunction, tissue regeneration, tumor therapy, and other diseases (Figure 2). Adipose-derived EVs are distinct from traditional adipokines and can function in specific tissues because of their contents.\textsuperscript{5} Zhou et al.\textsuperscript{90} found that after intravenous injection, EVs derived from brown adipose tissue (EV-BAT) preferentially accumulated in the liver, which suggested that the liver could be one of its key target organs. In addition, a small proportion of EV-BATs circulated into the spleen, lung, white adipose tissue (WAT), and heart.\textsuperscript{90} Another study further concluded that adipose tissue was a major source of circulating exosomal miRNAs by comparing exosomes from the serum of mice with an adipose-tissue-specific knockout of the miRNA-processing enzyme Dicer (ADicerKO) and wild-type mice.\textsuperscript{21} Moreover, they found exosomes derived from BAT targeted liver metabolism more specifically and...
efficiently than exosomes derived from WAT, which suggested that this exosome-mediated organ crosstalk might be tissue specific.90,91

Studies, to date, have not only obtained and applied natural adipose-derived EVs to disease models but also attempted to develop engineered EVs to deliver therapeutic, modified biomolecules, especially by modifying the contents of certain RNAs.92 A few loading strategies have been developed and adopted so far, including genetic engineering of target RNAs in parent cells, thus altering the certain contents in the EVs and direct modification of EV properties after isolation, such as loading target RNAs by electroporation.34,93 These RNA-related biomimetic approaches elegantly use existing RNA-mimic synthesis techniques, natural cell-binding ability, and close protection against RNases degradation of EVs.44,94 However, regardless of whether EVs have been modified, wide organ-crosstalk functions and the easy availability of adipose tissue have led to numerous studies exploring RNAs of adipose-derived EVs in the field of disease treatment. Importantly, under various sources (e.g., EVs derived from adipose tissue under high-fat feeding) and circumstances, RNAs derived from adipose tissue are not always beneficial against diseases but, sometimes, make them

| Table 1. Functional delivery of RNAs by adipose-derived EVs |
|---|
| **Process** | **Source** | **RNA** | **Function** | **Mechanism** | **Reference** |
| Metabolic regulation | BAT | miR-99b | Maintaining metabolic homeostasis | Decreasing FGF21 mRNA levels and repressing activity of a FGF21 3′-UTR reporter | 91 |
| | ATM | miR-155 | Inhibiting insulin signaling and glucose tolerance | Directly suppressing its target gene PPARY | 6 |
| | Mature adipocytes | miR-34a | Exacerbating obesity-induced, systemic inflammation, and metabolic dysregulation. | Suppressing M2 polarization by repressing the expression of Klf4 | 101 |
| Cutaneous healing | ASCs | lncRNA MALAT1 | Stimulating the healing of ischemic wounds | Promoting HDF cell migration and angiogenesis | 74 |
| | ASCs | miR-21 | Accelerating wound healing | Enhancing the migration and proliferation of HaCaT cells by increasing MMP-9 expression through the PI3K/AKT pathway | 109 |
| | ASCs | miR-125a | Promoting angiogenesis | Repressing expression of the angiogenic inhibitor Dll4 | 113 |
| Parenchymal organ repair | ASCs | miR-93-5p | Reducing AMI-induced myocardial damage | Suppressing hypoxia-induced autophagy and inflammatory cytokine expression by targeting Atg7 and TLR4 | 117 |
| | ASCs | miR-146a | Attenuating AMI-induced myocardial damage | Interacting with the 3′ UTR of EGR1 and suppressing posttranscriptional EGR1 expression | 62 |
| | ASCs | lncRNA H19 | Attenuating acute liver failure | Promoting hepatocyte proliferation | 116 |
| | ASCs | miR-181-5p | Attenuating liver fibrosis | Downregulating Stat3 and Bcl-2 and activating autophagy in hepatic stellate cells; downregulating collagen I, vimentin, α-SMA, and fibronectin in CCl4-induced liver fibrosis | 50 |
| Visceral adipose tissue | ASCs | miR-155 | Promoting intestinal inflammation | Promoting macrophage M1 polarization | 119 |
| | ASCs | miR-181b-5p | Promoting cerebral vascular remodeling | Promoting angiogenesis of brain microvascular endothelial cells after oxygen-glucose deprivation via miR-181b-5p/TRPM7 axis | 120 |
| Cancer | AT | circ-DB | Promoting HCC growth | Suppressing miR-34a and activating DB-related USP7 | 38 |
| | ASCs | miR-122 | Reducing HCC growth | Rendering HCC cells sensitive to chemotherapeutic agents and therefore increasing antitumor efficacy | 61 |
| | ASCs | miR-199a | Reducing HCC growth | Sensitizing HCC cells to doxorubicin by targeting mTOR and inhibiting mTOR pathway | 60 |

AT, adipose tissue; BAT, brown adipose tissue; ATM, adipose tissue macrophage; ASC, adipose-derived stem cell; miRNA, microRNA; HDF, human dermal fibroblast; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; Klf4, Krüppel-like factor 4; MMP-9, matrix metalloproteinase-9; STAT3, signal transducer and activator of transcription 3; Bcl-2, B cell lymphoma-2; FGF21, fibroblast growth factor 21; DLL4, delta-like ligand 4; circ-DB, circular RNA related to deubiquitylation (has_circ_0025129); AMI, acute myocardial infarction; EGR1, early growth response factor 1; HCC, hepatocellular carcinoma; TRPM7, transient receptor potential melastatin-subfamily member 7; USP7, ubiquitin-specific protease 7; UTR, untranslated region; TLR4, Toll-like receptor 4; mTOR, mechanistic target of rapamycin

www.moleculartherapy.org

Review
Only EVs containing RNAs with positive effects can serve as therapeutic candidates. Next, recent studies concerning the therapeutic potential of functional RNAs transferred by adipose-derived EVs will be specifically described in different clinical fields, which are summarized in Table 1, and abbreviations are summarized in Table 2.

**Metabolic disease**

Obesity is a concerning health issue that is generally characterized by excessive fat mass and quantity accumulation, which contributes to the occurrence of an array of complications, such as type 2 diabetes mellitus, hyperlipemia, and nonalcoholic fatty liver disease. Importantly, the secretion of adipocyte-derived EVs was increasingly enhanced under circumstances of chronic, low-grade metabolic disorders associated with obesity, which was stimulated by inflammatory cytokines, such as TNF-α and interferon-γ (IFN-γ). Therefore, adipose-derived EVs can be regarded as messengers of metabolic responses related to the pathophysiological state of obesity. Furthermore, the RNAs in adipose-derived EVs are now considered novel adipokines engaged in such metabolic regulation.

For instance, Thomou et al. first found exosomal miRNAs were significantly decreased in the serum of the ADicerKO mice, which endured severe metabolic disorders. Transplantation of BAT to the ADicerKO mice effectively restored the amount of circulating exosomal miRNAs and mitigated glucose intolerance with the level of fibroblast growth factor 21 (FGF21), a hormone that can regulate liver metabolism, remarkably reducing its circulation. Furthermore, miR-99b was highly expressed in BAT-derived exosomes and performed as a regulator in the expression of FGF21 in hepatocytes. Collectively, these findings implied the effects of brown adipocyte-derived exosomal miRNAs are adipokines that maintain metabolic homeostasis through transporting miR-99b and restraining production of FGF21.

Furthermore, as macrophages are well known to influence inflammation and insulin sensitivity, emerging evidence has explored...
important exosome-mediated crosstalk between adipose-derived EVs and macrophages that regulate immune and metabolic homeostasis.99,100 Ying et al.9 proved that ATMs from obese animals produced miRNAs from exosomes that could result in insulin resistance and glucose intolerance both in vitro and in vivo. Furthermore, miR-155 was found to be differentially expressed in obese Exo-ATMs, which could suppress insulin signaling and glucose tolerance by directly inhibiting its target gene PPARγ.6 Pan et al.107 reported that adipocyte-secreted exosomes could transport miR-34a to ATMs. Then, expression of Krüppel-like factor 4 (Klf4) and the polarization of M2 were both repressed, thereby exacerbating metabolic dysregulation and obesity-induced inflammation. Of note, they found that, after a high-fat feeding, adiponectin, a traditional adipokine positively related to insulin-sensitizing activity, was more-obviously upregulated in miR-34a-knockout mice than it was in wild-type littersmates. Moreover, the differential expression of adiponectin between these two groups disappeared after macrophage ablation, indicating that miR-34a had inhibiting effects on the production of adiponectin by indirectly modulating the quality of the macrophages.101,102 Collectively, these findings have offered new aspects of the complicated signaling mechanisms that connect RNAs of adipose-derived EVs and obesity-related metabolic diseases. Provided that these RNAs have been applied as specific biomarkers or tools, EV-based therapy may be much enhanced as a novel method of treating metabolic diseases.

Cutaneous healing and regeneration

Optimal cutaneous wound healing requires a well-arranged integration of the complicated biological and molecular regulation of cell proliferation and migration and of extracellular matrix aggregation and remodeling.103 Adipose tissue as an endocrine organ secretes a multitude of kinds of adipokines to regulate distant targets, including skin.104,105 Previous studies have shown that both the ASCs and adipose tissue lipoprotein extracellular fractions display therapeutic potential in wound healing.74,106 Moreover, as an indispensable component of extracellular fractions, adipose-derived EVs have also been demonstrated to take part in cutaneous wound healing.107,108 Studies have gone further to uncover the underlying biomolecular mechanisms of wound healing, which partly refer to the exact RNAs transferred by EVs. For example, Cooper et al.74 found that Exo-ASCs containing the IncRNA MALAT1 activated cell migration of human dermal fibroblasts in vitro and ischemic wound healing in vivo, whereas exosomes isolated from MALAT1-depleted conditioned medium were incapable of increasing cell migration. Another study109 illustrated that highly expressed miR-21 in Exo-ASCs could significantly accelerate the wound healing process and promote the proliferation and migration of HaCaT cells, which increased expression levels of matrix metalloproteinase-9 (MMP-9) in the PI3K/AKT pathway. In addition, Choi et al.110 performed an extensive analysis of miRNA expression between ASCs and Exo-ASCs and found Exo-ASCs contained many miRNAs (for example, miRNA-135a-5p, miRNA-378h, miRNA-586, and miRNA-1972) that could be related to fibroblast proliferation, ultraviolet protection, collagen synthesis, DNA repair, and cell aging, thus contributing to cutaneous restora-

Overall, studies of functional RNAs of adipose-derived EVs that provide meaningful insights into the intercellular communication and molecular mechanisms in the cutaneous regeneration process have mainly been conducted and verified in cell lines or primary cultures of keratinocytes, fibroblasts, or endothelial cells. There is no denying that these results may contribute greatly to new, promising, wound-healing therapies. Given the intricate cellular processes, diverse varieties, and multifactorial mediation of skin wounds, additional research related to cutaneous healing is needed to go deeply and profoundly into exploring different RNA functions in adipose-derived EVs.

Parenchymal organ repair and regeneration

As mentioned, in a growing number of parenchymal organ diseases, associated RNAs in adipose-derived EVs have been identified as endocrine factors that participate in those pathophysiological processes. In addition, the crosstalk between adipose tissue and other tissues or organs via RNAs have provided novel potential therapeutic applications for treatment of related diseases.

In the cardiovascular system, many miRNAs, such as miR-22-3p, miR-29c-3p, miR-26a-5p, and miR-125b-5p, have been found in EV-ASCs and are associated with cardioprotective properties.114 AMI is considered as one of the most common causes of death throughout the world.115 Studies have indicated that adipose-derived EVs could act as target RNA-transfected vehicles to mediate AMI-related therapy.62,116 For instance, Liu et al.117 demonstrated that miR-93-5p-enhanced Exo-ASCs had better protective effects on infarction-induced myocardial damage than natural exosome treatment, whereas in vitro results showed that miR-93-5p could exert an inhibiting effect on hypoxia-induced autophagy and inflammatory cytokine expression by acting on autophagy-related gene 7 (Atg7) and Toll-like receptor 4 (TLR4), respectively.118 Another similar study suggested that miR-146a-modified Exo-ASCs reduced AMI-induced myocardial damage by interacting with the 3’ UTR of early growth.
response factor 1 (EGFR) and suppressing expression of posttranscriptional EGR1 in vivo and in vitro. Research has also uncovered the important role of RNAs in the small EV (sEV)-mediated communication between adipose tissue and the liver. For example, IncRNA H19 released by EV-ASCs were proven to have a therapeutic role in acute liver failure by increasing the viability and proliferation of rat hepatocytes. Furthermore, in comparison with the treatment effects of EVs generated from non-silenced ASCs, the survival rate was significantly decreased when applying the coding sequence H19-silenced EV-ASCs to the treatment of rats with liver failure. Another study demonstrated that miR-181-5p-modified Exo-ASCs had a therapeutic effect on a liver fibrosis model. miR-181-5p-modified Exo-ASCs can downregulate Stat3 and Bcl-2 and stimulate autophagy in mouse hepatic stellate cells in vitro and reduce liver injury by downregulating collagen I, vimentin, a-SMA, and fibronectin in CCl4-induced liver fibrosis in vivo. In addition, because obesity can increase the risk of inflammatory bowel disease (IBD), Wei et al. found that the miRNA expression profile of visceral adipose exosomes was altered by a high-fat diet, which switched the exosomes from an anti-inflammatory phenotype to a pro-inflammatory phenotype. Furthermore, they revealed that circulating of exosomes from the obese fat transferred pro-inflammatory miR-155 to the colon, which promoted intestinal inflammation through accelerating macrophage M1 polarization. In addition, the exosome-mediated miR-155 inhibitor could prevent colitis as well. In the brain, the RNAs of adipose-derived EVs have been shown to enhance cerebral vascular remodeling after a stroke. The expression levels of miR-212-5p and miR-181b-5p were largely promoted in Exo-ASCs after ASCs were subjected to the brain extracts from rats with middle cerebral-artery occlusion, which showed that miR-212-5p and miR-181b-5p might be engaged in the development of an ischemic stroke. Additional studies have confirmed that, after oxygen-glucose deprivation treatment, the angiogenesis of brain microvascular endothelial cells was largely increased by Exo-ASCs through miR-181b-5p/transient receptor potential melastatin 7 (TRPM7) axis in vitro. Collectively, the RNAs of adipose-derived EVs have shown strong potential for clinical application in treating a few parenchymal organ diseases. Nevertheless, the organ disease models, which were proven to be effectively treated by EVs to date, have been restricted to organs or systems closely associated with adipose tissue, such as the liver and the cardiovascular system. Additional research related to other parenchymal organs is needed to fully disclose the RNA-mediated effects transferred by adipose-derived EVs.

Cancer
There is also growing interest in remolding RNAs of adipose-derived EVs into cancer therapeutic drugs. It appears that the RNAs of adipose-derived EVs have conflicting functions in regulating tumor progression, recognized as both promoting and suppressing effects in different types of tumors. For example, studies have demonstrated that the migration and proliferation of human breast carcinoma cell line MCF7 was significantly promoted by Exo-ASCs by activating Wnt/β-catenin signaling. Moreover, as we mentioned, circ-DB secreted by Exo-AT was found to be enriched in patients with HCC and larger fat ratios. Further studies have demonstrated that exosomal circ-DB enhances HCC growth by suppressing miR-34a and activating deubiquitination-related USP7, which positively affects tumor growth and results in poor survival rates. In addition, the effects of Exo-AT on HCC cells could be reversed by knockdown of circ-DB. Collectively, those results provide certain bright prospects for understanding the promotional effects of adipose tissue on malignant tumors.

In contrast, adipose-derived EVs were demonstrated to perform as tumor inhibitors. Lou et al. showed that miR-122, which has been proven to link with HCC development and progression, was successfully transfected in Exo-ASCs. The chemosensitivity to chemotherapeutic agents of cultured HCC cells was increased after uptake of these exosomes, and intra-tumor injection of these exosomes significantly increased the antitumor efficacy of chemotherapeutic agents in vivo, causing reduction in tumor growth. Similar research constructed miR-199a-modified Exo-ASCs, which could efficiently transfer miR-199a to HCC cells. Of note, miR-199a-modified Exo-ASCs remarkably sensitized HCC cells to doxorubicin by suppressing the mTOR pathway. Furthermore, intravenously injected miR-199a-modified Exo-ASCs dispersed to tumor tissues and significantly promoted the anticancer effects of doxorubicin against HCC in vivo. In summary, these studies undoubtedly indicate a novel anti-tumor clinical strategy of EV-ASCs via encapsulating either natural or engineered tumor-suppressing RNAs. However, new intense efforts are still needed to exploit the RNA-related functions and mechanisms of adipose-derived EVs in additional cancer types.

PERSPECTIVES
Adipose-derived EVs have gradually drawn growing attention and have displayed several potential applications because of their extensive range of sources and easy availability and because they act as endocrine factors. As mentioned, adipose tissue and adipose-derived stem cells secrete abundant RNA molecules into the blood circulation via extracellular vesicle trafficking. These RNAs are thought to participate in various intercellular communications, which promote target-organ crosstalk between adipose tissue, such as skin, liver, colon, and the cardiovascular system. Of note, because advanced microarray analyses and RNA-sequencing can accurately uncover the specific type and relative intensity of RNAs that are selectively recruited into EVs, it becomes much easier to investigate functional verifications and conduct mechanism experiments of RNAs. Additionally, recent novel studies, which used engineered adipose-derived EVs loaded with target RNAs, could further expand the clinical application of RNA-based EV therapeutics.

Although prospects seem bright, several problems remain to be discovered and overcome. First, the existence of contaminating RNAs of multiple lipoproteins or RNA-binding proteins is rarely studied. Certain EV-isolation methods may not be sufficient for wiping out the contamination of an EV-free RNA cargo, which will, of course, interfere with subsequent experiments of so-called EV-contained RNAs. For example, Karttunen et al. demonstrated...
that a precipitation-based EV-isolation method (e.g., the Invitrogen Total Exosome isolation) removed only portion of the plasma-vesicle-free miRNAs, which interferes with interpreting previous published data. Hence, further improvement of EV-isolation methods and identification of specific markers that show precisely the quality of the EV isolation and its purity are urgently required.

Another consideration comes from the RNA molecules themselves. RNAs in adipose-derived EVs contain a portion of non-coding RNAs, ranging in length from tens to thousands of nucleotides; however, target binding often involves partial complementarity with only a short length of nucleotides. When we artificially alter the amount of a certain novel RNAs in clinical trials, we should also pay attention to its targeting specificity, which may increase the possibility of unexpected and false conjunctions between RNAs and result in potential adverse effects in RNA-based EV therapeutics. Hence, detailed and careful assessments of any effects caused by target EV-contained RNAs are required in future clinical trials.

Last, but not least, adipose tissue is generally composed of multiple kinds of cells, such as mature adipocytes as well as a variety of stromal cells. The actual cellular sources of specific RNAs transferred by EVs as well as the relevant target pathways and tissues remain to be explored. In addition, many studies on the role of adipose-derived EVs in different organ crosstalk have been rather preliminary. Further intensive mechanistic and biosafety studies are required to better and comprehensively understand the role of RNAs transferred by EVs to be able to develop the potential of their clinical applications.

ACKNOWLEDGMENTS
This work was supported by National Key R&D Program of China (2017YFA0104800) and Key Technology R&D Program of Sichuan Province (2019YFS0312).

AUTHOR CONTRIBUTIONS
P.H., M.Y., and W.T. designed the concept. P.H. searched the literature regarding RNAs of adipose-derived EVs. P.H. wrote the manuscript and made the figures and tables. M.Y. and W.T. revised the manuscript. All authors read and approved the final manuscript.

DECLARATION OF INTERESTS
The authors declare no competing interests.

REFERENCES
1. Cinti, S. (2018). Adipose organ development and remodeling. Compr. Physiol. 15, 1357–1431.
2. Li, C., and Guo, X. (2019). The clinical potential of circulating microRNAs in obesity. Nat. Rev. Endocrinol. 15, 731–743.
3. Kita, S., Maeda, N., and Shimomura, I. (2019). Interorgan communication by exosomes, adipose tissue, and adiponectin in metabolic syndrome. J. Clin. Invest. 129, 4041–4049.
4. Funcke, J.B., and Scherrer, P.E. (2019). Beyond adiponectin and leptin: adipose tissue-derived mediators of inter-organ communication. J. Lipid Res. 60, 1648–1684.
5. Li, C.J., Fang, Q.H., Liu, M.L., and Lin, J.N. (2020). Current understanding of the role of adipose-derived extracellular vesicles in metabolic homeostasis and diseases: Communication from the distance between cells/tissues. Theranostics 10, 7422–7435.
6. Ying, W., Roipel, M., Bandyopadhyay, G., Dong, Y., Birmingham, A., Seo, J.B., Orefice, J.M., Wollam, J., Hernandez-Carretero, A., Fu, W., et al. (2017). Adipose tissue macrophage-derived exosomal miRNAs can modulate in vivo and in vitro insulin sensitivity. Cell 171, 372–384.e12.
7. Kim, K.M., Abdehmohsen, K., Mustapic, M., Kapogiannis, D., and Gorospe, M. (2017). RNA in extracellular vesicles. Wiley Interdiscip. Rev. RNA 8, 10.
8. Yáñez-Mó, M., Siljander, P.R., Andreu, Z., Zavec, A.B., Borris, F.E., Buzas, E.L., Buzas, K., Casal, E., Cappello, F., Carvalho, J., et al. (2015). Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles 4, 27066.
9. Théry, C., Witwer, K.W., Aikawa, E., Alcaraz, M.I., Anderson, J.D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin-Smith, G.K., et al. (2008). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J. Extracell. Vesicles 7, 1535750.
10. Hong, P., Yang, H., Wu, Y., Li, K., and Tang, Z. (2019). The functions and clinical application potential of exosomes derived from adipose mesenchymal stem cells: A comprehensive review. Stem Cell Res. Ther. 10, 242.
11. Wu, P., Zhang, B., Ocansey, D.K.W., Xu, W., and Qian, H. (2021). Extracellular vesicles: A bright star of nanomedicine. Biomaterials 269, 120467.
12. Kalluri, R., and LeBlue, V.S. (2020). The biology, function, and biomedical applications of exosomes. Science 367, eaao9777.
13. Stahl, P.D., and Raposo, G. (2019). Extracellular vesicles: exosomes and microvesicles, integrators of homeostasis. Physiology (Bethesda) 34, 169–177.
14. O’Brien, K., Breyne, K., Ughetto, S., Laurent, L.C., and Breakefield, X.O. (2020). RNA delivery by extracellular vesicles in mammalian cells and its applications. Nat. Rev. Mol. Cell Biol. 21, 585–606.
15. van Niel, G., D’Angelo, G., and Raposo, G. (2018). Shedding light on the cell biology of extracellular vesicles. Nat. Rev. Mol. Cell Biol. 19, 213–228.
16. Zhang, Y., Yu, M., and Tian, W. (2016). Physiological and pathological impact of exosomes of adipose tissue. Cell Physiol. 49, 3–13.
17. Nabhan, J.F., Hu, R., Oh, R.S., Cohen, S.N., and Lu, Q. (2012). Formation and release of arrestin domain-containing protein 1-mediated microvesicles (ARMMs) at plasma membrane by recruitment of TSG101 protein. Proc. Natl. Acad. Sci. USA 109, 4146–4151.
18. Born, L.J., Harmon, J.W., and Jay, S.M. (2020). Therapeutic potential of extracellular vesicle-associated long noncoding RNA. Bioeng. Transl. Med. 5, e10172.
19. Tsatsaronis, J.A., Franch-Arroyo, S., Resch, U., and Charpentier, E. (2018). Extracellular vesicle RNA: A universal mediator of microbial communication? Trends Microbiol. 26, 401–410.
20. Xu, R., Rai, A., Chen, M., Suwakulsiri, W., Greening, D.W., and Simpson, R.J. (2018). Extracellular vesicles in cancer—Implications for future improvements in cancer care. Nat. Rev. Clin. Oncol. 15, 617–638.
21. Xu, R., Greening, D.W., Zhu, H.J., Takahashi, N., and Simpson, R.J. (2016). Extracellular vesicle isolation and characterization: Toward clinical application. J. Clin. Invest. 126, 1152–1162.
22. Tetta, C., Ghigo, E., Silengo, L., Deregbus, M.C., and Camussi, G. (2013). Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine 44, 11–19.
23. Sinnivaan, S., Yeri, A., Cheah, P.S., Chung, A., Danielson, K., De Hoff, P., Filant, J., Laurent, C.D., Laurent, L.D., Magee, R., et al. (2019). Small RNA sequencing across diverse biotissues identifies optimal methods for exRNA isolation. Cell 177, 446–462.e16.
24. Jung, Y.I., Kim, H.K., Cho, Y., Choi, J.S., Woo, C.H., Lee, K.S., Sul, J.H., Lee, C.M., Han, J., Park, J.H., et al. (2020). Cell reprogramming using extracellular vesicles from differentiating stem cells into white/beige adipocytes. Sci. Adv. 6, eaay6721.
25. Chen, C.Y., Rao, S.S., Ren, L., Hu, X.K., Tan, Y.J., Hu, Y., Luo, J., Liu, Y.W., Yin, H., Huang, J., et al. (2018). Exosomal DMBT1 from human urine-derived stem cells...
facilitates diabetic wound repair by promoting angiogenesis. Theranostics 8, 1607–1623.
26. Dong, J., Wu, Y., Zhang, Y., Yu, M., and Tian, W. (2020). Comparison of the therapeutic effect of allogeneic and xenogenic small extracellular vesicles in soft tissue repair. Int. J. Nanomedicine 15, 6975–6991.
27. Xu, J., Wang, Y., Hsu, C.Y., Gao, Y., Meyers, C.A., Chang, L., Zhang, L., Broderick, K., Ding, C., Peault, B., et al. (2019). Human perivascular stem cell-derived extracellular vesicles mediate bone repair. LifeLine 8, e48191.
28. Xie, F., Zhou, X., Fang, M., Li, H., Su, P., Tu, Y., Zhang, L., and Zhou, F. (2019). Extracellular vesicles in cancer immune microenvironment and cancer immuno-therapy. Adv. Sci. (Weinh.) 6, 1901779.
29. Pezzana, C., Agnely, F., Bochot, A., Siepmann, J., and Menasché, P. (2021). Extracellular vesicles and biomaterial design: New therapies for cardiac repair. Trends Mol. Med. 27, 231–247.
30. Lou, P., Liu, S., Xu, X., Pan, C., Lu, Y., and Liu, J. (2021). Extracellular vesicle-based therapeutics for the regeneration of chronic wounds: Current knowledge and future perspectives. Acta Biomater. 119, 42–56.
31. Veerman, R.E., Güçüller Akpinar, G., Eldh, M., and Gabrielson, S. (2019). Immune cell-derived extracellular vesicles—Functions and therapeutic applications. Trends Mol. Med. 25, 382–394.
32. Prattichizzo, F., Matacchione, G., Giuliani, A., Sabbatinielli, J., Oliveri, F., de Candia, P., De Nigris, C., and Ceriello, A. (2021). Extracellular vesicle-shuttled miRNAs: A critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications. Theranostics 11, 1033–1045.
33. Shehzad, A., Islam, S.U., Shahzad, R., Khan, S., and Lee, Y.S. (2021). Extracellular vesicles in cancer diagnostics and therapeutics. Pharmacol. Ther. 221, 107806.
34. Zhang, B., Yang, Y., Xiang, L., Zhao, Z., and Ye, R. (2019). Adipose-derived exosomes: A novel adipokine in obesity-associated diabetes. J. Cell. Physiol. 234, 16602–16602.
35. Zhang, Y., Yu, M., Dai, M., Chen, C., Tang, Q., Jing, W., Wang, H., and Tian, W. (2017). miR-450a-5p within rat adipose tissue exosome-like vesicles promotes adipogenic differentiation by targeting WISP2. J. Cell Sci. 130, 1158–1168.
36. Erin, A., Riester, S.M., Zhu, X.-Y., Tang, H., Evans, J.M., O’Brien, D., van Wijnen, A.J., and Lerman, L.O. (2014). MicroRNA and mRNA cargo of extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. Gene 551, 55–64.
37. Jin, Y., Wang, J., Li, H., Gao, S., Shi, R., Yang, D., Wang, X., Wang, X., Zhu, L., Wang, X., et al. (2018). Extracellular vesicles secreted by human adipose-derived stem cells (hASCs) improve survival rate of rats with acute liver failure by releasing lncRNA h19. EBioMedicine 34, 231–242.
38. Zhang, H., Deng, T., Ge, S., Liu, Y., Bai, M., Zhu, K., Fan, Q., Li, J., Ning, T., Tian, F., et al. (2019). Exosome circRNA secreted from adipocytes promotes the growth of hepatocellular carcinoma by targeting deubiquitination-related USP7. Oncogene 38, 2844–2859.
39. Hinger, S.A., Cha, D.J., Franklin, J.L., Higginbotham, J.N., Dou, Y., Ping, J., Shu, L., Prasad, N., Levy, S., Zhang, B., et al. (2018). Diverse long RNAs are differentially enriched into extracellular vesicles from porcine adipose tissue-derived mesenchymal stem cells. PLoS ONE 12, e0174303.
40. Martin, P.J., Haren, N., Ghali, O., Clabaut, A., Chauveau, C., Hardouin, P., and Broux, O. (2015). Adipogenic RNAs are transferred to osteoblasts via bone marrow adipocytes-derived extracellular vesicles (EVs). BMC Cell Biol. 16, 10.
41. Chen, L., Wang, Y., Li, S., Zuo, B., Zhang, X., Wang, F., and Sun, D. (2020). Exosomes derived from GDNF-modified human adipose mesenchymal stem cells ameliorate periportal capillary loss in tubulointerstitial fibrosis by activating the SIRT1/eNOS signaling pathway. Theranostics 10, 9425–9442.
42. Bartel, D.P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116, 281–297.
43. Lewis, B.P., Shih, L.H., Jones-Rhoade, M.W., Bartel, D.P., and Burge, C.B. (2005). Prediction of mammalian microRNA targets. Cell 115, 788–798.
44. Carthew, R.W., and Sontheimer, E.J. (2009). Origins and mechanisms of miRNAs and siRNAs. Cell 136, 642–655.
45. Ameres, S.L., Martinez, J., and Schroeder, R. (2007). Molecular basis for target RNA recognition and cleavage by human RISC. Cell 130, 101–112.
46. Huang, B., Huang, L.F., Zhao, L., Zeng, W., Wang, X., Cao, D., Yang, L., Ye, Z., Chen, L., et al. (2019). Microvesicles (MVs) secreted from adipose-derived stem cells (ADSCs) contain multiple microRNAs and promote the migration and invasion of endothelial cells. Genes Dis. 7, 225–234.
47. Aday, S., Hazan-Haley, I., Chamorro-Jorganes, A., Arwar, M., Goldsmith, M., Beazley-Long, N., Sahoo, S., Dogra, N., Swead, N., Catapano, F., et al. (2021). Bioinspired artificial exosomes based on lipid nanoparticles carrying let-7b-5p promote angiogenesis in vitro and in vivo. Mol. Ther. 29, 2239–2252.
48. Dahluk, V.V., Fridslad, E., and Le Goff, W. (2020). Rewiring of lipid metabolism in adipose tissue macrophages in obesity: Impact on insulin resistance and type 2 diabetes. Int. J. Mol. Sci. 21, 5505.
49. Orlaguet, L., Ejalmanesh, T., and Alizad, F. (2020). Metabolic and molecular mechanisms of macrophage polarization and adipose tissue insulin resistance. Int. J. Mol. Sci. 21, 5731.
50. Prasad, N., Levy, S., Zhang, B., et al. (2018). Diverse long RNAs are differentially sorted into extracellular vesicles secreted by colorectal cancer cells. Cell Rep. 25, 715–725.e4.
51. Das, S., Ansel, K.M., Bitzer, M., Breakfield, X.O., Charest, A., Galas, D.J., Gerstein, M.B., Gupta, M., Milošević, A., McManus, M.T., et al.; Extracellular RNA Communication Consortium (2019). The extracellular RNA communication consortium: Establishing foundational knowledge and technologies for extracellular RNA research. Cell 177, 231–242.
52. Kossinova, O.A., Gopanenko, A.V., Tamkovich, S.N., Krassbenina, O.A., Tupkina, A.E., Kiseleva, E., Yushchina, D.D., Mahgyn, A.A., Ven‘yaminova, A.G., Kabalov, M.R., and Karpova, G.G. (2017). Cytosolic YB-1 and NSUN2 are the only proteins recognizing specific motifs present in mRNAs enriched in exosomes. Biochim. Biophys. Acta. Proteins Proteomics 1865, 664–673.
53. Fabbiano, F., Corsi, J., Guerrieri, E., Trevisan, C., Notarangelo, M., and D’Agostino, V.G. (2020). RNA packaging into extracellular vesicles: An orchestra of RNA-binding proteins? J. Extracell. Vesicles 10, e12043.
63. Batista, P.J., and Chang, H.Y. (2013). Long noncoding RNAs: Cellular address codes in development and disease. Cell 152, 1298–1307.
64. Kopp, F., and Mendell, J.T. (2018). Functional classification and experimental dissection of long noncoding RNAs. Cell 172, 393–407.
65. Bhan, A., Soleimani, M., and Mandal, S.S. (2017). Long noncoding RNA and cancer: A new paradigm. Cancer Res. 77, 3965–3981.
66. Chen, Y.G., Satpathy, A.T., and Chang, H.Y. (2017). Gene regulation in the immune system by long noncoding RNAs. Nat. Immunol. 18, 962–972.
67. Sarkar, D., Leung, E.Y., Baguley, B.C., Finlay, G.J., and Askarian-Amiri, M.E. (2015). Epigenetic regulation in human melanoma: Past and future. Epigenetics 10, 103–121.
68. Fatica, A., and Bozconi, I. (2014). Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15, 7–21.
69. Zhan, Z., Sun, W., Guo, Z., Zhang, J., Yu, H., and Liu, B. (2020). Mechanisms of IncRNA/microRNA interactions in angiogenesis. Life Sci. 254, 116900.
70. Ghafari-Fard, S., Esmaili, M., and Taheri, M. (2020). H19 IncRNA: Roles in tumorigenesis. Biomed. Pharmacother. 123, 109774.
71. Li, K., Wu, Y., Yang, H., Hong, P., Fang, X., and Hu, Y. (2019). H19/miR-30a/C8orf4 axis modulates the adipogenic differentiation process in human adipose tissue-derived mesenchymal stem cells. J. Cell. Physiol. 234, 20925–20934.
72. Zhang, Y., Wang, F., Chen, G., He, R., and Yang, L. (2019). LncRNA MALAT1 promotes osteoarthritis by modulating miR-150-5p/AKT3 axis. Cell Biosci. 9, 54.
73. Patel, N.A., Moss, L.D., Lee, J.Y., Tajiri, N., Acosta, S., Hudson, C., Parag, S., Cooper, D.R., Borlongan, C.V., and Bickford, P.C. (2018). Long noncoding RNA MALAT1 in exosomes drives regenerative function and modulates inflammation-linked networks following traumatic brain injury. J. Neuroinflammation 15, 204.
74. Cooper, D.R., Wang, C., Patel, R., Trujillo, A., Patel, N.A., Prather, J., Gould, L.J., and Wu, M.H. (2018). Human adipose-derived stem cell conditioned media and exosomes containing MALAT1 promote human dermal fibroblast migration and ischemic wound healing. Adv. Wound Care (New Rochelle) 7, 299–308.
75. Song, Y., Li, H., Ren, X., Li, H., and Feng, C. (2020). SNHG9, delivered by adipocyte-derived exosomes, alleviates inflammation and apoptosis of endothelial cells through suppressing TRADD expression. Eur. J. Pharmacol. 872, 172977.
76. Shao, M., Jin, M., Xu, S., Zheng, C., Zhu, W., Ma, X., and Lv, F. (2020). Exosomes from long noncoding RNA-gm37494-adscs repair spinal cord injury via shifting miR-133/145/miR-206 axis. Mol. Cells 43, 701–711.
77. Verduci, L., Strano, S., Yarden, Y., and Blandino, G. (2019). The circRNA-miRNA code: Emerging implications for cancer diagnosis and treatment. Mol. Oncol. 13, 669–680.
78. Meng, S., Zhou, H., Feng, Z., Xu, Z., Tang, Y., Li, P., and Wu, M. (2017). CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol. Cancer 16, 94.
79. Li, X., Yang, L., and Chen, L.L. (2018). The biogenesis, functions, and challenges of circular RNAs. Mol. Cell 71, 428–442.
80. Li, Z., Zhu, X., and Huang, S. (2020). Extracellular vesicle long non-coding RNAs and circular RNAs: Biology, functions and applications in cancer. Cancer Lett. 489, 111–120.
81. Ma, S., Niu, M., Hao, Z., Liu, M., Tong, C., and Zhao, X. (2021). Selective packaged extracellular vesicles of adipose tissue-derived mesenchymal stem cells promote wound healing in diabetic mice by inducing miR-123-3p/SIRT1-mediated autophagy. Am. J. Physiol. Cell Physiol. 318, C848–C856.
82. Du, W.W., Zhang, C., Wang, Y., Yong, T., Awan, F.M., and Yang, B.B. (2017). Identifying and characterizing circRNA-protein interaction. Theranostics 7, 4183–4191.
83. Zhang, X., Chen, L., Xiao, B., Liu, H., and Su, Y. (2019). Circ_0075932 in adipocyte-derived exosomes induces inflammation and apoptosis in human dermal keratinocytes by directly binding with PUM2 and promoting PUM2-mediated activation of AuroraA/NEF-kB pathway. Biochem. Biophys. Res. Commun. 511, 551–558.
84. Zhou, X., Li, Z., Qi, M., Zhao, P., Duan, Y., Yang, G., and Yuan, L. (2020). Brown adipose tissue-derived exosomes mitigate the metabolic syndrome in high fat diet mice. Theranostics 10, 8197–8210.
85. Thomou, T., Mori, M.A., Dreyfuss, J.M., Konishi, M., Sakaguchi, M., Wolfrum, C., Rao, T.N., Winnay, J.N., Garcia-Martín, R., Grinspoon, S.K., et al. (2017). Adipose-derived circulating miRNAs regulate gene expression in other tissues. Nature 542, 450–455.
86. Armstrong, J.P., Holme, M.N., and Stevens, M.M. (2017). Re-engineering extracellular vesicles as smart nanoscale therapeutics. ACS Nano 11, 69–83.
87. El-Andaloussi, S., Lee, Y., Lakhil-Littleton, S., Li, J., Seow, Y., Gardiner, C., Alvarez-Erviti, L., Sargent, I.L., and Wood, M.J. (2012). Exosome-mediated delivery of siRNA in vitro and in vivo. Nat. Protoc. 7, 2112–2126.
88. de Abreu, R.C., Fernandes, H., da Costa Martins, P.A., Sahoo, S., Emanuelli, C., and Ferreira, L. (2020). Native and bioengineered extracellular vesicles for cardiovascular therapeutics. Nat. Rev. Cardiol. 17, 685–697.
89. Ghaben, A.L., and Scherer, P.E. (2019). Adipogenesis and metabolic health. Nat. Rev. Mol. Cell Biol. 20, 242–258.
90. Ouchi, N., Parker, J.L., Lugus, J.J., and Walsh, K. (2011). Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97.
91. Kusminski, C.M., Bickel, P.E., and Scherer, P.E. (2016). Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15, 639–660.
92. Durcin, M., Fleury, A., Taillébost, E., Hilairet, G., Krupova, Z., Henry, C., Truchet, S., Trotzmüller, M., Kofler, H., Mabileaux, G., et al. (2017). Characterisation of adipocyte-derived extracellular vesicle subtypes identifies distinct protein and lipid signatures for large and small extracellular vesicles. J. Extracell. Vesicles 6, 1305677.
93. Zhao, H., Shang, Q., Pan, Z., Bai, Y., Li, Z., Zhang, H., Zhang, Q., Guo, C., Zhang, L., and Wang, Q. (2018). Exosomes from adipose-derived stem cells attenuate adipose inflammation and obesity through polarizing m2 macrophages and beiging in white adipose tissue. Diabetes 67, 235–247.
94. Chawla, A., Nguyen, K.D., and Goh, Y.P.S. (2011). Macrophage-mediated inflammation in metabolic disease. Nat. Rev. Immunol. 11, 738–749.
95. Pan, Y., Hui, X., Hoo, R.L.C., Ye, D., Chan, C.Y.C., Feng, T., Wang, Y., Lam, K.S.L., and Xu, A. (2019). Adipocyte-secreted exosomal microRNA-34a inhibits M2 macrophage polarization to promote obesity-induced adipose inflammation. J. Clin. Invest. 129, 834–849.
96. Maeda, N., Shimomura, I., Kishiida, K., Nishizawa, H., Matsuda, M., Nagaretani, H., Furuyama, N., Kondo, H., Takahashi, M., Arita, Y., et al. (2002). Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat. Med. 8, 731–737.
97. Falanga, V. (2005). Wound healing and its impairment in the diabetic foot. Lancet 365, 1736–1743.
98. Kovács, D., Fazekas, F., Oláh, A., and Törökcsik, D. (2020). Adipokines in the skin and in dermatological diseases. Int. J. Mol. Sci. 21, 9048.
105. Romacho, T., Elsen, M., Röhrborn, D., and Eckel, J. (2014). Adipose tissue and its role in organ crosstalk. Acta Physiol. (Oxf.) 210, 733–753.

106. Bellai, R., Migliano, E., Tedesco, M., Caputo, S., Papaccio, F., Lopez, G., and Picardo, M. (2018). Adipose tissue-derived extracellular fraction characterization: biological and clinical considerations in regenerative medicine. Stem Cell Res. Ther. 9, 207.

107. Zhang, W., Bai, X., Zhao, B., Li, Y., Zhang, Y., Li, Z., Wang, X., Luo, L., Han, F., Zhang, J., et al. (2018). Cell-free therapy based on adipose tissue stem cell-derived exosomes promotes wound healing via the PI3K/Akt signaling pathway. Exp. Cell Res. 370, 333–342.

108. Ren, S., Chen, J., Duscher, D., Liu, Y., Guo, G., Kang, Y., Xiong, H., Zhan, P., Wang, Y., Wang, C., et al. (2019). Microvesicles from human adipose stem cells promote wound healing by optimizing cellular functions via AKT and ERK signaling pathways. Stem Cell Res. Ther. 10, 47.

109. Yang, C., Luo, L., Bai, X., Shen, K., Liu, K., Wang, J., and Hu, D. (2020). Highly-expressed microRNA-21 in adipose derived stem cell exosomes can enhance the migration and proliferation of the HaCaT cells by increasing the MMP-9 expression through the PI3K/AKT pathway. Arch. Biochem. Biophys. 681, 108259.

110. Choi, E.W., Seo, M.K., Woo, E.Y., Kim, S.H., Park, E.J., and Kim, S. (2018). Exosomes from human adipose-derived stem cells promote proliferation and migration of skin fibroblasts. Exp. Dermatol. 27, 1170–1172.

111. Choi, J.S., Cho, W.L., Choi, Y.J., Kim, J.D., Park, H.A., Kim, S.Y., Park, J.H., Jo, D.G., and Cho, Y.W. (2019). Functional recovery in photo-damaged human dermal fibroblasts by human adipose-derived stem cell extracellular vesicles. J. Extracell. Vesicles 8, 1565885.

112. Gentile, P., and Garcovich, S. (2021). Adipose-derived mesenchymal stem cells (ad-mscs) against ultraviolet (UV) radiation effects and the skin photaging. Biomedicines 9, 532.

113. Liang, X., Zhang, L., Wang, S., Han, Q., and Zhao, R.C. (2016). Exosomes secreted by mesenchymal stem cells promote endothelial cell angiogenesis by transferring miR-125a. J. Cell Sci. 129, 2182–2189.

114. Nazari-Shahi, T.Z., Neuber, S., Duran, A.G., Exarchos, V., Beier, C.M., Meyborg, H., Kruger, K., Wolint, P., Buschmann, J., Böni, R., et al. (2020). miRNA profiles of extracellular vesicles secreted by mesenchymal stromal cells—Can they predict potential off-target effects? Biomolecules 10, 1353.

115. Aydin, S., Uğur, K., Aydin, S., Sahin, I., and Yardim, M. (2019). Biomarkers in acute myocardial infarction: Current perspectives. Vasc. Health Risk Manag. 15, 1–10.

116. Luo, Q., Guo, D., Liu, G., Chen, G., Hang, M., and Jin, M. (2017). Exosomes from mir-126-overexpressing adscs are therapeutic in relieving acute myocardial ischemic injury. Cell. Physiol. Biochem. 44, 2105–2116.

117. Liu, J., Jiang, M., Deng, S., Lu, J., Huang, H., Zhang, Y., Gong, P., Shen, X., Ruan, H., Jin, M., and Wang, H. (2018). Mir-93-5p-containing exosomes treatment attenuates acute myocardial infarction-induced myocardial damage. Mol. Ther. Nucleic Acids 11, 103–115.

118. Yan, C., Tian, X., Li, J., Liu, D., Ye, D., Xie, Z., Han, Y., and Zhou, M.H. (2021). A high-fat diet attenuates Ahpfr z1 in adipocytes to induce exosome shedding and nonalcoholic fatty liver development in vivo. Diabetes 70, 577–588.

119. Wei, M., Gao, X., Liu, L., Li, Z., Wan, Z., Dong, Y., Chen, X., Niu, Y., Zhang, J., and Yang, G. (2020). Visceral adipose tissue derived exosomes exacerbate colitis severity via pro-inflammatory miRNAs in high fat diet fed mice. ACS Nano 14, 5099–5110.

120. Yang, Y., Cai, Y., Zhang, Y., Liu, J., and Xu, Z. (2018). Exosomes secreted by adipose-derived stem cells contribute to angiogenesis of brain microvascular endothelial cells following oxygen-glucose deprivation in vitro through microRNA-181b/TRPM7 axis. J. Mol. Neurosci. 65, 74–83.

121. Lin, R., Wang, S., and Zhao, R.C. (2013). Exosomes from human adipose-derived mesenchymal stem cells promote migration through Wnt signaling pathway in a breast cancer cell model. Mol. Cell. Biochem. 383, 13–20.

122. Wu, J., Kumar, S., Wang, F., Wang, H., Chen, L., Arsenault, P., Mattern, M., and Weinstock, J. (2018). Chemical approaches to intervening in ubiquitin specific protease 7 (USP7) function for oncology and immune oncology therapies. J. Med. Chem. 61, 422–443.

123. Tsai, W.C., Hsu, C.S., Lai, T.C., Chen, S.J., Shen, R., Huang, Y., Chen, H.C., Lee, C.H., Tsai, T.F., et al. (2012). MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J. Clin. Invest. 122, 2884–2897.

124. Stranka, R., Gysbrechts, L., Wouters, J., Vermeersch, P., Bloch, K., Dietrickx, D., Andrei, G., and Snoeck, R. (2018). Comparison of membrane affinity-based method with size-exclusion chromatography for isolation of exosome-like vesicles from human plasma. Transl. Med. 16, 1.

125. Karttunen, J., Heiskanen, M., Navarro-Ferrandis, V., Das Gupta, S., Lipponen, A., Puhakka, N., Rilla, K., Koutinen, A., and Pitkänen, A. (2018). Precipitation-based extracellular vesicle isolation from rat plasma co-precipitate vesicle-free microRNAs. J. Extracell. Vesicles 8, 1555410.

126. Gorski, S.A., Vogel, J., and Doudna, J.A. (2017). RNA-based recognition and targeting: sowing the seeds of specificity. Nat. Rev. Mol. Cell Biol. 18, 215–228.